Orthobond
Monmouth Junction, US · Delaware corporation
Orthobond develops proprietary antimicrobial nanosurface technology that covalently binds to metallic and polymeric surfaces to mechanically kill bacteria, viruses, and fungi without antibiotics or eluting chemicals. Its first products, including Ostaguard, are antimicrobial surface treatments for implantable medical devices, with intended future applications in textiles, consumer goods, and high-touch public surfaces.
Founders & leadership
Competitors · 5
by search overlapCompanies competing with Orthobond for the same Google search keywords, organic and paid, via search-intersection analysis.
Reported raises · per SEC filings
Form D private placements▶$1.1MraisedSep 2022 · 8 investors · Other TechnologyRule 506(b)
- David NicholsExecutive Officer, Director
- Peter GoodwinDirector
- Frank CammisaDirector
- Khalil BarrageDirector
- Lisa D'UrsoDirector
- David HelfetDirector
- Peter K. ScaturroDirector
- Gregory LutzDirector
- Paul VolovichExecutive Officer
- Offering amount
- $15M
- Amount sold
- $1.1M
- Minimum investment
- $50K
- Sales commissions
- $750K
- Placement agents
- Kola Agbaje
- First sale
- Sep 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2022 | $146.4K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.